A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

PHASE3CompletedINTERVENTIONAL
Enrollment

471

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

March 31, 2011

Conditions
Parkinson's Disease
Interventions
DRUG

IPX066

extended-release carbidopa-levodopa capsules

DRUG

IR CD-LD

immediate-release carbidopa-levodopa tablets

Trial Locations (73)

1307

Investigator 30, Sachsen

8028

Investigator 70, Barcelona

8036

Investigator 57, Barcelona

8190

Investigator 45, Barcelona

8221

Investigator 43, Terrassa

10032

Investigator 12, New York

10437

Investigator 23, Berlin

11725

Investigator 8, Commack

12163

Investigator 72, Berlin

12208

Investigator 25, Albany

13088

Investigator 28, Berlin

13353

Investigator 67, Berlin

20125

Investigator 62, Bucharest

21000

Investigator 22, Dijon

21005

Investigator 56, Vinnitsa

26655

Investigator 27, Westerstede

27607

Investigator 9, Raleigh

27707

Investigator 11, Durham

28006

Investigator 50, Madrid

28922

Investigator 53, Madrid

29401

Investigator 14, Charleston

30912

Investigator 46, Augusta

31059

Investigator 33, Toulouse

33021

Investigator 61, Hollywood

33713

Investigator 4, St. Petersburg

33980

Investigator 15, Port Charlotte

Investigator 8, Port Charlotte

34205

Investigator 64, Bradenton

34471

Investigator 5, Ocala

35233

Investigator 17, Birmingham

43614

Investigator 42, Toledo

45219

Investigator 20, Cincinnati

48025

Investigator 1, Bingham Farms

49005

Investigator 55, Dnipro

50309

Investigator 39, Des Moines

53233

Investigator 2, Milwaukee

59037

Investigator 52, Lille

60611

Investigator 19, Chicago

60612

Investigator 40, Chicago

61068

Investigator 44, Kharkiv

65117

Investigator 66, Odesa

66160

Investigator 29, Kansas City

67091

Investigator 32, Strasbourg

69035

Investigator 41, Zaporizhzhya

69600

Investigator 47, Zaporizhzhya

72205

Investigator 7, Little Rock

74137

Investigator 60, Tulsa

75013

Investigator 58, Paris

80045

Investigator 51, Aurora

83003

Investigator 71, Donetsk

83702

Investigator 38, Boise

85013

Investigator 49, Phoenix

90502

Investigator 6, Torrance

92037

Investigator 3, La Jolla

94085

Investigator 31, Sunnyvale

98405

Investigator 65, Tacoma

500283

Investigator 68, Brasov

540136

Investigator 69, Târgu Mureş

Investigator 63, Târgu Mureş

06510

Investigator 10, New Haven

08901

Investigator 21, New Brunswick

75390-9016

Investigator 16, Dallas

77030-2744

Investigator 13, Houston

N6A 5A5

Investigator 24, London

K1G 4G3

Investigator 18, Ottawa

G1R 3X5

Investigator 26, Québec

85-796

Investigator 48, Bydgoszcz

31-530

Investigator 37, Krakow

20-718

Investigator 59, Lublin

02-777

Investigator 36, Warsaw

70-215

Investigator 54, Szczecin

62-050

Investigator 35, Mosina

40-546

Investigator 34, Katowice

Sponsors
All Listed Sponsors
lead

Impax Laboratories, LLC

INDUSTRY

NCT00974974 - A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD). | Biotech Hunter | Biotech Hunter